$57.67 +0.07 (%) Merck & Co Inc - NYSE

Jul. 2, 2015 | 04:00 PM

Partner Headlines

  1. Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint

    Benzinga | Jun. 29, 2015 | 08:31AM EST
  2. Intrexon Corp is expanding his business

    GuruFocus | Jun. 25, 2015 | 12:54PM EST
  3. Just How Big Can Leaders Skyworks, Valeant Grow In Market Cap?

    IBD | Jun. 22, 2015 | 18:52PM EST
  4. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story

    GuruFocus | Jun. 22, 2015 | 18:34PM EST
  5. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD | Jun. 22, 2015 | 13:56PM EST
  6. Stocks Jump At The Starting Bell; Macom And Paycom Head IBD 50 Stocks

    IBD | Jun. 22, 2015 | 10:46AM EST
  7. MERCK's

    IBD | Jun. 17, 2015 | 18:41PM EST
  8. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga | Jun. 16, 2015 | 18:04PM EST
  9. New Migraine Drugs Could Ease Investors' Headaches

    IBD | Jun. 11, 2015 | 08:02AM EST
  10. TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

    Benzinga | Jun. 10, 2015 | 07:02AM EST
  11. Benzinga's M&A Chatter for Monday June 8, 2015

    Benzinga | Jun. 8, 2015 | 20:17PM EST
  12. TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

    Benzinga | Jun. 8, 2015 | 16:30PM EST
  13. Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

    IBD | Jun. 5, 2015 | 12:47PM EST
  14. 3 Dividend Leaders That Just Broke Out Of Bases

    IBD | Jun. 4, 2015 | 18:23PM EST
  15. Merck Announces Results from Investigational IMPROVE-IT Study of VYTORIN Published in NEJoM

    Benzinga | Jun. 3, 2015 | 17:00PM EST
  16. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus | Jun. 3, 2015 | 15:32PM EST
  17. ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

    IBD | Jun. 1, 2015 | 17:48PM EST
  18. Bristol Dives On Cancer Drug

    IBD | May. 29, 2015 | 18:43PM EST
  19. Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

    IBD | May. 29, 2015 | 16:22PM EST
  20. Merck got EU's CHMP

    IBD | May. 22, 2015 | 18:22PM EST
  21. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus | May. 21, 2015 | 10:48AM EST
  22. Puma Crashes, Roche Rises On Cancer Data News

    IBD | May. 14, 2015 | 12:59PM EST
  23. Intrexon

    IBD | May. 11, 2015 | 18:46PM EST
  24. MERCK

    IBD | May. 11, 2015 | 18:46PM EST
  25. Merck's Stock Price, Dividend Yield Beating S&P 500

    IBD | May. 6, 2015 | 18:13PM EST
  26. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus | May. 4, 2015 | 19:24PM EST
  27. Biogen Making A Breakthrough In Treating Alzheimer's

    GuruFocus | May. 2, 2015 | 16:04PM EST
  28. Big Pharma Beats Wall St.

    IBD | Apr. 28, 2015 | 19:11PM EST
  29. Merck Jumps, United Therapeutics Drops On Q1 Earnings

    IBD | Apr. 28, 2015 | 18:50PM EST
  30. Stocks Recover Off Lows, End Mixed; Twitter Crashes

    IBD | Apr. 28, 2015 | 16:16PM EST
  31. Stocks Recover After Volatile Start; Merck Props Up Dow

    IBD | Apr. 28, 2015 | 14:47PM EST
  32. Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

    IBD | Apr. 28, 2015 | 12:47PM EST
  33. Stocks Recover From Iran News, Weak Consumer Confidence

    IBD | Apr. 28, 2015 | 12:04PM EST
  34. Stock Futures Mixed, Nasdaq Up; Apple, Vasco, Merck Rising

    IBD | Apr. 28, 2015 | 09:02AM EST
  35. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 28, 2015 | 08:21AM EST
  36. Merck Beats Q1 Estimates, Shares Rise

    Benzinga | Apr. 28, 2015 | 08:08AM EST
  37. After Hours: Merck Perks; Pot Biotech Is A Downer

    IBD | Apr. 27, 2015 | 20:00PM EST
  38. MERCK

    IBD | Apr. 27, 2015 | 18:45PM EST
  39. 4 Drug Giants Reporting Earnings This Week

    IBD | Apr. 27, 2015 | 13:33PM EST
  40. Does Apple Hide More Cash Abroad Than Anyone?

    Benzinga | Apr. 26, 2015 | 13:21PM EST
  41. U.S. Tech, Dollar & Health Care ETFs To Watch This Week

    Benzinga | Apr. 26, 2015 | 10:52AM EST
  42. Cancer Drugs Impress Again

    IBD | Apr. 20, 2015 | 18:43PM EST
  43. Bristol, Merck Cancer Drugs Strut Their Stuff

    IBD | Apr. 20, 2015 | 11:29AM EST
  44. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 16:31PM EST
  45. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD | Apr. 17, 2015 | 16:14PM EST
  46. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD | Apr. 17, 2015 | 10:44AM EST
  47. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD | Apr. 14, 2015 | 14:37PM EST
  48. UPDATE: Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

    Benzinga | Apr. 14, 2015 | 13:30PM EST
  49. Robert Bruce's Top Growth Stocks

    GuruFocus | Apr. 13, 2015 | 21:36PM EST
  50. Fast Money Picks For March 2

    Benzinga | Mar. 1, 2015 | 18:54PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!